PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses
Haghmorad, D.; Yousefi, B.; Eslami, M.; Rashidy-Pour, A.; Tarahomi, M.; Tavaf, M.J.; Soltanmohammadi, A.; Zargarani, S.; Kamyshnyi, A.; Oksenych, V. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses. Current Issues in Molecular Biology 2022, 44, 5728–5740, doi:10.3390/cimb44110388.
Haghmorad, D.; Yousefi, B.; Eslami, M.; Rashidy-Pour, A.; Tarahomi, M.; Tavaf, M.J.; Soltanmohammadi, A.; Zargarani, S.; Kamyshnyi, A.; Oksenych, V. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses. Current Issues in Molecular Biology 2022, 44, 5728–5740, doi:10.3390/cimb44110388.
Haghmorad, D.; Yousefi, B.; Eslami, M.; Rashidy-Pour, A.; Tarahomi, M.; Tavaf, M.J.; Soltanmohammadi, A.; Zargarani, S.; Kamyshnyi, A.; Oksenych, V. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses. Current Issues in Molecular Biology 2022, 44, 5728–5740, doi:10.3390/cimb44110388.
Haghmorad, D.; Yousefi, B.; Eslami, M.; Rashidy-Pour, A.; Tarahomi, M.; Tavaf, M.J.; Soltanmohammadi, A.; Zargarani, S.; Kamyshnyi, A.; Oksenych, V. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses. Current Issues in Molecular Biology 2022, 44, 5728–5740, doi:10.3390/cimb44110388.
Abstract
Multiple sclerosis (MS) is a demyelinating autoimmune disorder of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) has been widely used to determine the pathogenesis of the disease and evaluate new treatment strategies for MS. Therefore, we investigated the efficacy of oral administration of a Myelin Oligodendrocyte Glycoprotein (MOG) in the treatment of EAE. Female C57BL/6 mice were utilized in three groups (Control group: received PBS orally; prevention group: oral administration of MOG35-55 two weeks before EAE induction; treatment group: oral administration of MOG35-55 after EAE induction. MOG administration, both as prevention and treatment, significantly controlled clinical score, weight loss, CNS inflammation, and demyelination, mainly through the modulation of T cell proliferation, reduction of pro-inflammatory cytokines and transcription factors, including TNF-α, IFN-γ, IL-17, T-bet, and ROR-γt. MOG administration, both as prevention and treatment, also induced anti-inflammatory cytokines and transcription factors, including IL-4, TGF-β, GATA-3, and Foxp3. The results showed that oral administration of MOG, both as prevention and treatment, could efficiently control EAE development. Immunomodulatory mechanisms include the induction of Th2 and Treg cells and the suppression of pro-inflammatory Th1 and Th17 cells.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.